AU2005266225A1 - Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle - Google Patents

Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle Download PDF

Info

Publication number: AU2005266225A1
Authority: AU; Australia
Prior art keywords: product; cpg; tumor; group; cells
Prior art date: 2004-06-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2005266225A

Other languages

English (en)

Inventor

Antoine Carpentier

Lluis Mir

Caroline Robert

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

OLIGOVAX

Centre National de la Recherche Scientifique CNRS

Institut Gustave Roussy (IGR)

Universite Paris Descartes

Original Assignee

OLIGOVAX

Centre National de la Recherche Scientifique CNRS

Institut Gustave Roussy (IGR)

Universite Paris Descartes

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-25

Filing date

2005-06-24

Publication date

2006-02-02

2004-10-22 Priority claimed from EP04292515A external-priority patent/EP1649859A1/fr

2005-06-24 Application filed by OLIGOVAX, Centre National de la Recherche Scientifique CNRS, Institut Gustave Roussy (IGR), Universite Paris Descartes filed Critical OLIGOVAX

2006-02-02 Publication of AU2005266225A1 publication Critical patent/AU2005266225A1/en

Status Abandoned legal-status Critical Current

Links

230000003308 immunostimulating effect Effects 0.000 title claims description 31
230000001093 anti-cancer Effects 0.000 title claims description 17
238000009792 diffusion process Methods 0.000 title claims description 6
206010028980 Neoplasm Diseases 0.000 claims description 136
229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims description 77
229940046166 oligodeoxynucleotide Drugs 0.000 claims description 59
210000004027 cell Anatomy 0.000 claims description 46
238000011282 treatment Methods 0.000 claims description 31
201000011510 cancer Diseases 0.000 claims description 25
238000004520 electroporation Methods 0.000 claims description 24
239000000126 substance Substances 0.000 claims description 22
239000000427 antigen Substances 0.000 claims description 20
108091007433 antigens Proteins 0.000 claims description 20
102000036639 antigens Human genes 0.000 claims description 20
108091034117 Oligonucleotide Proteins 0.000 claims description 17
239000003446 ligand Substances 0.000 claims description 15
102000002689 Toll-like receptor Human genes 0.000 claims description 12
108020000411 Toll-like receptor Proteins 0.000 claims description 12
210000004881 tumor cell Anatomy 0.000 claims description 12
108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 9
102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 9
230000005684 electric field Effects 0.000 claims description 8
108010006654 Bleomycin Proteins 0.000 claims description 7
206010027476 Metastases Diseases 0.000 claims description 7
229960001561 bleomycin Drugs 0.000 claims description 7
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 7
230000001472 cytotoxic effect Effects 0.000 claims description 7
231100000433 cytotoxic Toxicity 0.000 claims description 6
239000000284 extract Substances 0.000 claims description 5
231100000024 genotoxic Toxicity 0.000 claims description 5
230000001738 genotoxic effect Effects 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 4
230000000340 anti-metabolite Effects 0.000 claims description 3
229940100197 antimetabolite Drugs 0.000 claims description 3
239000002256 antimetabolite Substances 0.000 claims description 3
230000000694 effects Effects 0.000 description 26
241000699670 Mus sp. Species 0.000 description 23
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
239000000047 product Substances 0.000 description 18
230000000259 anti-tumor effect Effects 0.000 description 17
241001465754 Metazoa Species 0.000 description 14
230000028993 immune response Effects 0.000 description 12
241000699666 Mus <mouse, genus> Species 0.000 description 11
230000004913 activation Effects 0.000 description 11
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
238000002512 chemotherapy Methods 0.000 description 10
210000004443 dendritic cell Anatomy 0.000 description 10
238000000338 in vitro Methods 0.000 description 10
108020004414 DNA Proteins 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
210000000987 immune system Anatomy 0.000 description 9
230000028327 secretion Effects 0.000 description 9
238000009169 immunotherapy Methods 0.000 description 8
210000001165 lymph node Anatomy 0.000 description 8
210000004698 lymphocyte Anatomy 0.000 description 8
210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 8
238000012552 review Methods 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
230000009885 systemic effect Effects 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
230000003013 cytotoxicity Effects 0.000 description 7
231100000135 cytotoxicity Toxicity 0.000 description 7
238000000034 method Methods 0.000 description 7
230000004044 response Effects 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
102000004127 Cytokines Human genes 0.000 description 6
108090000695 Cytokines Proteins 0.000 description 6
201000008808 Fibrosarcoma Diseases 0.000 description 6
241001529936 Murinae Species 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
230000006698 induction Effects 0.000 description 6
239000002609 medium Substances 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
230000006641 stabilisation Effects 0.000 description 6
238000011105 stabilization Methods 0.000 description 6
108020000946 Bacterial DNA Proteins 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
210000000822 natural killer cell Anatomy 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 5
108010065805 Interleukin-12 Proteins 0.000 description 4
102000013462 Interleukin-12 Human genes 0.000 description 4
108010075205 OVA-8 Proteins 0.000 description 4
230000001772 anti-angiogenic effect Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
201000001441 melanoma Diseases 0.000 description 4
238000001959 radiotherapy Methods 0.000 description 4
238000011084 recovery Methods 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
102000006992 Interferon-alpha Human genes 0.000 description 3
108010047761 Interferon-alpha Proteins 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000009227 antibody-mediated cytotoxicity Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000002619 cancer immunotherapy Methods 0.000 description 3
230000001461 cytolytic effect Effects 0.000 description 3
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000036039 immunity Effects 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
238000011740 C57BL/6 mouse Methods 0.000 description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
102000004889 Interleukin-6 Human genes 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
HQXFJGONGJPTLZ-YTMOPEAISA-N [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl n-[(2s)-2-amino-3-hydroxypropanoyl]sulfamate Chemical compound O[C@@H]1[C@H](O)[C@@H](COS(=O)(=O)NC(=O)[C@H](CO)N)O[C@H]1N1C2=NC=NC(N)=C2N=C1 HQXFJGONGJPTLZ-YTMOPEAISA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000006023 anti-tumor response Effects 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
230000030833 cell death Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
238000011254 conventional chemotherapy Methods 0.000 description 2
229960004397 cyclophosphamide Drugs 0.000 description 2
230000007423 decrease Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
210000001163 endosome Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
230000015788 innate immune response Effects 0.000 description 2
210000005007 innate immune system Anatomy 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
238000002372 labelling Methods 0.000 description 2
230000008949 local secretion Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
230000035515 penetration Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
150000004713 phosphodiesters Chemical class 0.000 description 2
-1 phosphor diesters Chemical class 0.000 description 2
150000003057 platinum Chemical class 0.000 description 2
230000000861 pro-apoptotic effect Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
101150072531 10 gene Proteins 0.000 description 1
208000034723 Amelia Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000000058 Anaplasia Diseases 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
208000006586 Ectromelia Diseases 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
101000845188 Homo sapiens Tetratricopeptide repeat protein 4 Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 1
101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
206010024503 Limb reduction defect Diseases 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
241001467552 Mycobacterium bovis BCG Species 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108091081548 Palindromic sequence Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
108700012920 TNF Proteins 0.000 description 1
102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
102100031279 Tetratricopeptide repeat protein 4 Human genes 0.000 description 1
241000906446 Theraps Species 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
239000000061 acid fraction Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
238000011394 anticancer treatment Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
230000005975 antitumor immune response Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
101150093710 clec-87 gene Proteins 0.000 description 1
238000001246 colloidal dispersion Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000003596 drug target Substances 0.000 description 1
239000012636 effector Substances 0.000 description 1
239000008393 encapsulating agent Substances 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
210000001808 exosome Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
229960004783 fotemustine Drugs 0.000 description 1
YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229940029575 guanosine Drugs 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008076 immune mechanism Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
239000000568 immunological adjuvant Substances 0.000 description 1
230000006054 immunological memory Effects 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
229940117681 interleukin-12 Drugs 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
230000007108 local immune response Effects 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000015654 memory Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
210000000274 microglia Anatomy 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000006654 negative regulation of apoptotic process Effects 0.000 description 1
OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical class NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000008823 permeabilization Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000013379 physicochemical characterization Methods 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000011521 systemic chemotherapy Methods 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000000357 thermal conductivity detection Methods 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
238000012800 visualization Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2005266225A 2004-06-25 2005-06-24 Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle Abandoned AU2005266225A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP04291615.5		2004-06-25
EP04291615		2004-06-25
EP04292515A EP1649859A1 (fr)	2004-10-22	2004-10-22	Produits pharmaceutiques contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant sous forme d'oligodésoxynucléotide
EP04292515.6		2004-10-22
PCT/FR2005/001612 WO2006010838A2 (fr)	2004-06-25	2005-06-24	Produits contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant

Publications (1)

Publication Number	Publication Date
AU2005266225A1 true AU2005266225A1 (en)	2006-02-02

Family

ID=35515626

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2005266225A Abandoned AU2005266225A1 (en)	2004-06-25	2005-06-24	Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle

Country Status (3)

Country	Link
EP (1)	EP1765361A2 (fr)
AU (1)	AU2005266225A1 (fr)
WO (1)	WO2006010838A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006054129A1 (fr)	2004-11-19	2006-05-26	Institut Gustave Roussy	Traitement ameliore du cancer par arn double brin
FR2975600B1 (fr) *	2011-05-24	2013-07-05	Assist Publ Hopitaux De Paris	Agents pour le traitement de tumeurs
GB201408119D0 (en)	2014-05-08	2014-06-25	Univ Cork	Method
JP7409773B2 (ja)	2015-07-31	2024-01-09	リージェンツオブザユニバーシティオブミネソタ	改変された細胞および治療の方法
US20200208111A1 (en) *	2016-06-09	2020-07-02	Branden S. Moriarity	Genome-edited nk cell and methods of making and using

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU760549B2 (en) *	1998-04-03	2003-05-15	University Of Iowa Research Foundation, The	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
FR2790955B1 (fr) *	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral

2005
- 2005-06-24 EP EP05783840A patent/EP1765361A2/fr not_active Withdrawn
- 2005-06-24 WO PCT/FR2005/001612 patent/WO2006010838A2/fr not_active Ceased
- 2005-06-24 AU AU2005266225A patent/AU2005266225A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2006010838A3 (fr)	2006-06-15
WO2006010838A2 (fr)	2006-02-02
EP1765361A2 (fr)	2007-03-28

Publication	Publication Date	Title
Temizoz et al.	2016	Vaccine adjuvants as potential cancer immunotherapeutics
RU2468819C2 (ru)	2012-12-10	Новые синтетические агонисты tlr9
AU2005257938B2 (en)	2010-11-11	Immunostimulatory oligonucleotide multimers
CN104507538B (zh)	2018-04-06	癌症免疫疗法的组合物和方法
AU2002359516B2 (en)	2006-02-02	Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist
CN105228450A (zh)	2016-01-06	用于活化“干扰素基因刺激因子”-依赖性信号传导的组合物和方法
ES3035198T3 (en)	2025-08-29	Cpg amphiphiles and uses thereof
AU2016227629B2 (en)	2022-02-24	Method
KR20060124669A (ko)	2006-12-05	하나 이상의 톨 유사 수용체 7 또는 톨 유사 수용체 8작용물질 및 톨 유사 수용체 4 작용물질을 포함하는면역자극 조성물
Wang et al.	2005	Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics
JP2024509935A (ja)	2024-03-05	免疫細胞療法における両親媒性物質の使用及びそのための組成物
MXPA04011127A (es)	2005-07-01	Oligonucleotidos inmuno estimuladores metilados y metodos para utilizar los mismos.
Sharma et al.	2003	Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors
AU2005266225A1 (en)	2006-02-02	Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle
KR20230002140A (ko)	2023-01-05	신규한 리보핵산 및 이를 기반으로 하는 약제학적 조성물
Tomai et al.	2012	TLR agonists as vaccine adjuvants
KR102375057B1 (ko)	2022-03-17	Hsp90 항원성 펩타이드를 포함하는 항암용 백신 조성물
WO2018060514A1 (fr)	2018-04-05	Procédés et compositions combinant au moins un agoniste du récepteur de reconnaissance de motif (prr) avec un anticorps anti-récepteur il10
AU2014280133B2 (en)	2016-12-15	Pharmaceutical compositions comprising a GPG oligodeoxynucleotide and cyclic di-GMP
EP1649859A1 (fr)	2006-04-26	Produits pharmaceutiques contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant sous forme d'oligodésoxynucléotide
RU2823677C2 (ru)	2024-07-29	Cpg амфифилы и их применения
Wang et al.	2011	Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia
WO2016135286A1 (fr)	2016-09-01	Procédé de stimulation de cellules dendritiques (dc)
AU2006200116B2 (en)	2009-03-19	Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist
Ag et al.	2015	PARADIGMS REGARDING THE ADJUVANTICITY OF NUCLEIC ACIDS FOR CANCER VACCINES

Legal Events

Date	Code	Title	Description
2009-05-14	MK1	Application lapsed section 142(2)(a) - no request for examination in relevant period